Monthly dermatology bulletin — November 16, 2026
This issue covers October 17 to November 16, 2026, following the October 16 issue. It was a month heavy on industry announcements and light on peer-reviewed publications: of the six verified items, four come from press releases or congress presentations and should be read as preliminary. The most important finding of the month is oncologic: a positive phase 3 trial of a personalized mRNA vaccine in resected melanoma.
Atopic dermatitis, psoriasis, and hidradenitis suppurativa
1. Lutikizumab, an anti–IL-1α/β, with a positive phase 3 trial in hidradenitis suppurativa (INTREPID)
[Industry] [Multinational / USA]
On October 22, AbbVie announced topline results of the randomized, double-blind, placebo-controlled phase 3 INTREPID trial (NCT06468228): 1,400 adults and adolescents with moderate to severe hidradenitis suppurativa, randomized 1:1 to subcutaneous lutikizumab or placebo. At week 16, 31.4% achieved HiSCR75 vs 23.4% with placebo (p ≤ 0.001); all 8 ranked secondary endpoints were also met, including NRS30 pain reduction at week 8 (at least a 30% and at least a 2-unit reduction in worst skin pain, among patients with baseline NRS ≥3: 36.0% vs 22.8%) and fewer flares over weeks 1 to 16 (18.4% vs 28.1%). Adverse events were similar to placebo (53.4% vs 53.7%; serious 3.0% vs 2.9%), with oral candidiasis in 0.3% vs 0.4%.
Why it matters: it opens a pathway distinct from IL-17 in HS, but the absolute difference over placebo is only 8 points, doses have not been disclosed, and the data come from a manufacturer press release without peer review; regulatory submission is planned for the second half of 2027, so practice in the Dominican Republic will not change in the short term.
Sources
- [Official release] AbbVie, October 22, 2026. https://news.abbvie.com/2026-10-22-AbbVie-Announces-Topline-Results-from-the-Phase-3-INTREPID-Trial-Showing-Lutikizumab-Significantly-Improved-Signs-and-Symptoms-of-Disease-in-Patients-with-Hidradenitis-Suppurativa
- [Coverage] Healio, October 26, 2026. https://www.healio.com/news/dermatology/20261026/lutikizumab-achieves-rigorous-bar-for-hidradenitis-suppurativa-response-topline-data
2. Anti-TSLP bosakitug fails to beat placebo in atopic dermatitis (ADMIRATION)
[Industry] [USA]
On November 16, Aclaris Therapeutics reported that the phase 2 ADMIRATION trial of bosakitug (ATI-045), an anti-TSLP monoclonal antibody, in moderate to severe atopic dermatitis did not meet its primary endpoint (percent change in EASI at week 24) or its secondary endpoints. The company describes good tolerability and downregulation of Th1, Th2, and Th17 biomarkers, but disclosed no efficacy figures or adverse event rates. According to the company's earlier releases, the trial is randomized, double-blind, and placebo-controlled, with 109 patients enrolled.
Why it matters: a negative result for a target of interest; the lack of figures makes it impossible to judge whether the molecule, dose, or design failed.
Sources
- [Official release] Aclaris Therapeutics, November 16, 2026. https://www.globenewswire.com/news-release/2026/11/16/3403198/37216/en/aclaris-therapeutics-announces-top-line-phase-2-results-for-its-anti-tslp-monoclonal-antibody-bosakitug-ati-045-in-atopic-dermatitis-ad.html
- [Official release] Aclaris Therapeutics, November 16, 2026 (copy filed with the SEC). https://www.sec.gov/Archives/edgar/data/1557746/000110465926127478/acrs-ex99d1.htm
- [Official release] Aclaris Therapeutics, March 18, 2026 (enrollment completed: 109 patients). https://investor.aclaristx.com/node/13511
3. Brepocitinib (TYK2/JAK1 inhibitor) in cutaneous sarcoidosis: phase 2 in JAMA Dermatology (BEACON)
[Clinical trial] [USA]
Prespecified week-16 interim analysis of a randomized, double-blind, placebo-controlled phase 2 trial conducted at 18 US sites and published on November 10 in JAMA Dermatology (Rosenbach et al.): 31 adults (13 on 45 mg/day, 11 on 15 mg/day, and 7 on placebo; 13 with lupus pernio). With 45 mg, CSAMI-A fell by about 22.3 points vs 0.7 with placebo; CSAMI-A 50% response was 76.9% vs 0%, and 9 of 13 patients (69.2%) achieved clear or almost clear on CSA-IGA (score of 0 or 1 with an improvement of at least 2 categories) vs none on placebo. Adverse events were mostly mild, with one case of worsening preexisting anemia that resolved after discontinuation.
Why it matters: it is a historically neglected disease, according to the authors, and the effect is large, but with 31 patients, a 7-patient placebo arm, and sponsorship by Priovant, the phase 3 BEACON+ trial (140 patients, results expected in 2028) is needed.
Sources
- [Article] Rosenbach M, Shields BE, Coates M, et al. Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis: A Phase 2 Randomized Clinical Trial. JAMA Dermatol. Published online November 10, 2026. DOI: 10.1001/jamadermatol.2026.5444. Open access (CC BY-NC-ND). https://doi.org/10.1001/jamadermatol.2026.5444
- [Coverage] Managed Healthcare Executive, November 10, 2026. https://www.managedhealthcareexecutive.com/view/positive-phase-2-results-reported-for-lisraya-as-a-treatment-for-cutaneous-sarcoidosis
- [Coverage] Dermatology Times, November 10, 2026. https://www.dermatologytimes.com/view/brepocitinib-clears-skin-in-69-of-cutaneous-sarcoidosis-patients
Skin cancer and melanoma
4. Personalized mRNA vaccine plus pembrolizumab cuts the risk of recurrence by 42% in resected melanoma (INTerpath-001)
[Congress] [Multinational; presented at ESMO 2026, Madrid]
In the phase 3 INTerpath-001 trial (NCT05933577; LBA1, Long et al., presented October 24), 1,137 patients with resected stage IIB–IV melanoma were randomized 2:1 to pembrolizumab 400 mg every 6 weeks plus intismeran autogene (individualized neoantigen vaccine, 1 mg IM every 3 weeks, up to 9 doses; n = 757) or placebo (n = 380). At a median follow-up of 24.6 months, recurrence-free survival improved with HR 0.58 (95% CI, 0.45–0.75): 82.2% vs 70% at 2 years; distant metastasis-free survival HR 0.62 (95% CI, 0.45–0.85; 88.5% vs 80.2%). Overall survival is immature (HR 0.77; 95% CI, 0.45–1.31; not significant). Grade 3–5 treatment-related adverse events occurred at similar rates (14.2% vs 13.4%); pyrexia (52.2%) and injection-site pain (51%) predominated.
Why it matters: a positive phase 3 trial of a personalized cancer vaccine that could change adjuvant therapy, but overall survival is pending and per-patient manufacturing poses a serious cost and logistics problem for Latin America and the Caribbean; the trial is sponsored by Merck and Moderna.
Sources
- [Coverage] Healio, October 23, 2026. https://www.healio.com/news/hematology-oncology/20261023/personalized-mrna-vaccine-reduced-melanoma-recurrence-risk-42-after-surgery
- [Coverage] CancerNetwork, October 24, 2026. https://www.cancernetwork.com/view/interpath-001-data-detail-survival-subgroup-and-safety-findings-in-melanoma
Photodermatoses and rare diseases
5. Bitopertin in erythropoietic protoporphyria: positive phase 3 after an FDA complete response letter (APOLLO)
[Industry] [USA, Canada, Europe, and Australia]
On October 19, Disc Medicine announced results of the randomized, double-blind, placebo-controlled phase 3 APOLLO trial (NCT06910358): 183 patients aged 12 or older with erythropoietic protoporphyria or X-linked protoporphyria, randomized 1:1 to oral bitopertin 60 mg/day (a glycine transporter 1 inhibitor) or placebo for 6 months. Metal-free protoporphyrin IX fell 41.4% vs placebo (p < 0.0001). During month 6, the between-group difference in average monthly total time in light without pain was 12.2 hours (p = 0.0010); phototoxic reactions also decreased. The most frequent adverse event with bitopertin was dizziness (50%), generally mild or moderate and transient.
Why it matters: it provides the link between protoporphyrin reduction and a clinical benefit in sunlight that the FDA required when it issued a complete response letter to the accelerated approval application on February 13, 2026; the company plans to resubmit by the end of 2026. Press release data, not peer reviewed.
Sources
- [Registry] NCT06910358, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06910358
- [Official release] Disc Medicine, October 19, 2026. https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-success-all-primary-and-secondary
- [Official release] Disc Medicine, October 19, 2026 (copy filed with the SEC). https://www.sec.gov/Archives/edgar/data/1816736/000119312526424649/d156263dex991.htm
- [Coverage] HCPLive, October 19, 2026. https://www.hcplive.com/view/bitopertin-meets-all-endpoints-phase-3-apollo-trial-epp
Dermoscopy and artificial intelligence
6. DEXI, explainable AI on dermoscopy, to guide biopsy decisions (Mayo Clinic Proceedings)
[Publication] [USA]
Retrospective Mayo Clinic study published in Mayo Clinic Proceedings, including 261 lesions from 178 patients with total-body photography, sequential digital dermoscopy, and histologic diagnosis. At a DEXI threshold of 3.0, the tool correctly ruled out 75% of benign lesions; mean scores were 2.5 for benign lesions, 6.0 for melanomas, and 7.8 for nonmelanoma skin cancer.
Why it matters: in this sample, 25% of benign lesions scored above the threshold (false positives); because these lesions had already been selected for biopsy, that figure cannot be used to estimate how many biopsies the tool would generate in a screening population. This is a retrospective single-institution study; it needs prospective and external validation before clinical use.
Sources
- [Article] Mayo Clin Proc. 2026. DOI: 10.1016/j.mayocp.2026.07.031. https://www.mayoclinicproceedings.org/article/S0025-6196(26)18701-1/abstract
- [Official release] Mayo Clinic, October 22, 2026. https://newsnetwork.mayoclinic.org/?p=418962
- [Coverage] News-Medical, October 22, 2026. https://news-medical.net/news/20261022/AI-scoring-tool-may-guide-skin-biopsy-decision.aspx
Ready-to-paste WhatsApp text
*Monthly dermatology bulletin — November 2026* Greetings, colleagues. What we verified from October 17 to November 16: 🔬 *Inflammatory diseases* *Lutikizumab in hidradenitis suppurativa (INTREPID, phase 3)* HiSCR75 at week 16: 31.4% vs 23.4% with placebo; n = 1,400. Press release only. https://news.abbvie.com/2026-10-22-AbbVie-Announces-Topline-Results-from-the-Phase-3-INTREPID-Trial-Showing-Lutikizumab-Significantly-Improved-Signs-and-Symptoms-of-Disease-in-Patients-with-Hidradenitis-Suppurativa *Anti-TSLP bosakitug fails in atopic dermatitis (phase 2)* It missed its primary and secondary endpoints. https://www.globenewswire.com/news-release/2026/11/16/3403198/37216/en/aclaris-therapeutics-announces-top-line-phase-2-results-for-its-anti-tslp-monoclonal-antibody-bosakitug-ati-045-in-atopic-dermatitis-ad.html *Brepocitinib in cutaneous sarcoidosis (JAMA Dermatology)* CSAMI-A 50 response: 76.9% vs 0% with 45 mg; only 31 patients. https://www.managedhealthcareexecutive.com/view/positive-phase-2-results-reported-for-lisraya-as-a-treatment-for-cutaneous-sarcoidosis 🎯 *Melanoma* *Personalized mRNA vaccine + pembrolizumab (INTerpath-001)* Risk of recurrence or death −42% (HR 0.58); 2-year RFS 82.2% vs 70%. https://www.healio.com/news/hematology-oncology/20261023/personalized-mrna-vaccine-reduced-melanoma-recurrence-risk-42-after-surgery 🧬 *Rare diseases* *Bitopertin in erythropoietic protoporphyria (APOLLO)* Month 6: +12.2 h of monthly pain-free time in light vs placebo. https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-success-all-primary-and-secondary 🤖 *AI* *DEXI (Mayo): dermoscopic AI to guide biopsy decisions* Threshold 3.0: ruled out 75% of benign lesions; retrospective, no external validation yet. https://news-medical.net/news/20261022/AI-scoring-tool-may-guide-skin-biopsy-decision.aspx Full bulletin and audio: https://boletinesmedicos.com/en/dermatology/2026-11-16.html MedBulletins · boletinesmedicos.com
Ready-to-paste LinkedIn post
Monthly dermatology bulletin — November 16, 2026 6 verified items from the past month: ESMO 2026, JAMA Dermatology, Mayo Clinic Proceedings, and manufacturer announcements. Three worth your time: • Personalized mRNA vaccine + pembrolizumab in resected melanoma (INTerpath-001, phase 3): risk of recurrence or death −42% (HR 0.58); 82.2% vs 70% recurrence-free at 2 years. Overall survival pending; cost and logistics are a challenge for the region. • Lutikizumab (anti–IL-1α/β) in hidradenitis suppurativa (INTREPID, n = 1,400): HiSCR75 31.4% vs 23.4%. Modest difference, press release only. • Brepocitinib (TYK2/JAK1 inhibitor) in cutaneous sarcoidosis (phase 2, JAMA Dermatology): CSAMI-A 50 response 76.9% vs 0% with 45 mg. Large effect, but only 31 patients. Full bulletin, with a critical appraisal of each study and links to its sources: https://boletinesmedicos.com/en/dermatology/2026-11-16.html #Dermatology #AtopicDermatitis #Melanoma #HidradenitisSuppurativa #AIinMedicine
Ready-to-paste X (Twitter) post
Dermatology, Nov 2026: personalized mRNA vaccine + pembrolizumab cuts recurrence risk 42% in resected melanoma (HR 0.58). Brepocitinib in cutaneous sarcoidosis: CSAMI-A 50 response 76.9% vs 0% (phase 2, n = 31). https://boletinesmedicos.com/en/dermatology/2026-11-16.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.